drugset / Trial / NCT00757731

FMS European Long-Term Study

NCT00757731

Phase 3 Completed 490 enrolled Pierre Fabre Laboratories
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Investigation of the long-term (12 months) efficacy and safety of milnacipran used in the treatment of fibromyalgia syndrome.

Timeline

Start
2006-09
Primary completion
2008-10
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Milnacipran Other / unclassified 100 mg
Subject Milnacipran Other / unclassified 150 mg
Subject Milnacipran Other / unclassified 200 mg

Indications